Search

everythinglearnresearchcommunity

for

Search:↓

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

Hair transplants, oral finasteride, oral minoxidil, and dutasteride mesotherapy are highly effective for treating AGA hair loss. This combination can maintain and improve hair for most people, except those with very aggressive AGA.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

GLA may help with hair loss due to its anti-inflammatory properties and 5ar enzyme inhibition. It's considered potentially more important than biotin, especially for those already using finasteride and dutasteride.

A natural compound called C3A from Aronia Chokeberry can help prevent hair loss by counteracting the effects of DHT. The user has been taking 50 grams of dried organic Aronia Chokeberry daily for 30 days and will update with photos in 60 days.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

A user's extreme regimen for hair loss, which includes taking oral and topical medications such as minoxidil, dutasteride, cyproterone acetate and bicalutamide, but still experiencing miniaturization. Suggestions were made to try other treatments such as RU58841 and Pyrilutamide, while also considering mental health treatment and advice on lookmaxxing.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.

The conversation discusses the idea of creating finasteride gummies for hair loss treatment, with some users expressing skepticism about their effectiveness compared to pills. Concerns include the potential for reduced drug delivery in gummy form and the risk of children mistaking them for candy.

Researching and developing an effective local antagonist to block the androgen receptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.